ArticleAsian Pacific journal of cancer prevention : APJCP2024
Molecular Profile of BCR-ABL1 Negative Myeloproliferative Neoplasm in a Moroccan Population.
Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMyeloproliferative neoplasms (MPN) are associated with clonal hematopoiesis, genomic instability, hemostasis dysregulation, and immune response. Classic BCR-ABL1 negative myeloproliferative neoplasms (BCR-ABL1 negative MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are frequently associated with somatic abnormalities in JAK2, CALR, and MPL. Mutant clones induce an inflammatory immune response leading to immuno-thrombosis.
objectiveThe aim of this research was to investigate JAK2/STAT5 mutations in 49 Moroccan patients and to study their correlation with demographic and hematological parameters.
methodGenomic DNA was isolated from peripheral blood samples, and JAK2V617F, JAK2 exon 12, CALR exon 9, and MPL exon 10 mutations were tested by qPCR, AS-PCR, and Sanger sequencing. Statistical analysis was performed using SPSS version 22.
resultsOur results showed that 33 (67.35%) of our cohort was mutated for one of the investigated genes. JAK2V617F was detected in 25 cases, as well as two previously described CALR mutations: c.1092_1143del52 and c.1154_1155insTTGTC. Mutations in JAK2 exon 12 (c.1622G>A/C and c.1641+6T>C) were observed and in PV and ET. MPL substitution c.1544G>T was detected in two cases. Mutations in JAK2, CALR, and MPL were mutually exclusive and benign single nucleotide variations/polymorphisms (SNV/SNP) have been identified in CALR and JAK2. The JAK2-PV subgroup was associated with higher red mass cell, hemoglobin, and hematocrit levels. Higher platelet counts correlated with the JAK2-ET subgroup, while higher leukocyte and neutrophil counts were associated with the JAK2-PMF subgroup. Complete blood count revealed hyperleukocytosis accompanied by hyperplateletosis and a lower level of hemoglobin in CALR-ET mutated patients, compared to JAK2-ET mutated or triple negative-ET cases.
conclusionIn conclusion, our study provides valuable insights into the prevalence and characteristics of JAK2, CALR, and MPL mutations in BCR-ABL1 negative MPNs in the Moroccan population, highlighting the importance of genetic characterization to optimize the clinical management of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.